文献速递免疫规划

利用S100A4损伤相关分子模式佐剂活性构建抗结核黏膜疫苗制剂

A mucosal vaccine formulation against tuberculosis by exploiting the adjuvant activity of S100A4-A damage-associated molecular pattern molecule.
PubMed 文献 · Vaccine · 2024-08-01

研究评估由结核分枝杆菌特异性抗原ESAT-6与新型黏膜佐剂S100A4组成的鼻内结核疫苗配方。小鼠鼻内给予重组ESAT-6联合或不联合S100A4,结果显示S100A4可诱导Mtb特异性适应性免疫应答,显著提高血清抗ESAT-6 IgG及黏膜IgA水平,促进CD4 T细胞扩增及IFN-γ、TNF-α、IL-17表达,并增强脾脏T细胞增殖应答和CD8 T细胞颗粒酶B表达。

要点

  • S100A4作为黏膜佐剂可增强ESAT-6鼻内免疫的Mtb特异性抗体应答。
  • S100A4促进肺和脾脏ESAT-6特异性CD4 T细胞扩增及细胞因子表达。
  • S100A4佐剂化免疫可能预示良好的黏膜抗结核保护作用。

核心结论

  • S100A4佐剂化鼻内免疫可能预示良好的黏膜抗结核保护作用。

研究设计与样本

  • 小鼠鼻内给予重组ESAT-6联合或不联合S100A4作为佐剂。

主要发现

  • S100A4显著提高血清抗ESAT-6 IgG以及肺渗出液、支气管肺泡灌洗液(BALF)和鼻灌洗液等黏膜部位IgA水平。
  • S100A4在肺和脾组织中强烈促进ESAT-6特异性CD4 T细胞扩增。
  • 肺和脾组织中CD4与CD8 T细胞表达更高水平的IFN-γ、TNF-α和IL-17。
  • S100A4佐剂化小鼠脾脏中抗原再遇诱导的T细胞增殖应答增强。
  • S100A4佐剂化小鼠脾和肺组织CD8 T细胞在抗原再刺激后表达更高水平的颗粒酶B。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB), remains one of the top three causes of death. Currently, the only licensed vaccine against TB is the bacillus Calmette-Guerin (BCG), which lacks efficacy in preventing and controlling pulmonary TB in adults. We aimed to evaluate a nasal TB vaccine formulation composed of the Mtb-specific vaccine antigen ESAT-6, an Mtb-associated protein that can trigger protective immune responses, and S100A4, a recently characterized novel mucosal adjuvant. Mice were intranasally given recombinant ESAT-6 in the presence or absence of S100A4 as an adjuvant. We have provided experimental evidence demonstrating that S100A4 admixed to ESAT-6 could induce Mtb-specific adaptive immune responses after intranasal immunization. S100A4 remarkably augmented the levels of anti-ESAT-6 IgG in serum and IgA in mucosal sites, including lung exudates, bronchoalveolar lavage fluid (BALF) and nasal lavage. Furthermore, in both lung and spleen tissues, S100A4 strongly promoted ESAT-6-specific expansion of CD4 T cells. Both CD4 and CD8 T cells from these tissues expressed increased levels of IFN-γ, TNF-α, and IL-17, cytokines critical for antimicrobial activity. Antigen-reencounter-induced T cell proliferative responses, a key vaccine performance indicator, were augmented in the spleen of S100A4-adjuvanted mice. Furthermore, CD8 T cells from the spleen and lung tissues of these mice expressed higher levels of granzyme B upon antigen re-stimulation. S100A4-adjuvanted immunization may predict good mucosal protection against TB.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Abil OZ, Liu S, Yeh YW, et al. A mucosal vaccine formulation against tuberculosis by exploiting the adjuvant activity of S100A4-A damage-associated molecular pattern molecule. Vaccine. 2024. PMID: 39089961. doi:10.1016/j.vaccine.2024.07.052

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。